Tysabri poised for return to market : "Competition looming It remains to be seen how Tysabri will fare in terms of sales when it is back on the market. Schering Ag Adr's Betaferon/Betaseron (interferon beta- 1b), Teva Neuroscience's Copaxone (glatiramer acetate), Serono S.A's Novantrone (mitoxantrone hydrochloride) and Serono/Pfizer's Rebif (r-IFN-B1a) loom as Tysabri's main competitors, while
Serono's Mylinax (cladribine) (expected to file for regulatory approval in 2008) and Autolmmune Inc's MBP8298 are two drugs in Phase III trials that are also expected to be in competition with Tysabri